Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (3,820,000)	$ (3,579,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment	10,000	162,000
Redeemable warrants valuation adjustment	(31,000)	37,000
Amortization of patent, trademark rights	19,000	65,000	$ 116,000
Changes in ROU assets	5,000	11,000
Loss on available for sale marketable securities	19,000	2,000
Gain from sale of income tax operating losses	(190,000)	(181,000)
Equity-based compensation	242,000	526,000
Unrealized loss on marketable securities	915,000
Amortization of finance and debt issuance costs		36,000
Change in assets and liabilities:
Prepaid expenses and other current assets and other non current assets	8,000	26,000
Lease liability	(5,000)	(11,000)
Accounts payable	180,000	(194,000)
Accrued expenses	(110,000)	55,000
Net cash used in operating activities	(2,758,000)	(3,045,000)
Cash flows from investing activities:
Proceeds from sale of marketable securities	407,000	2,039,000
Purchase of marketable securities	(720,000)	(1,151,000)
Purchase of patent and trademark rights	(33,000)	(365,000)
Net cash (used in) provided by investing activities	(346,000)	523,000
Cash flows from financing activities:
Financing obligation payments		(93,000)
Proceeds from sale of stock, net of issuance costs		12,887,000
Net cash provided by financing activities		12,794,000
Net (decrease) increase in cash and cash equivalents	(3,104,000)	10,272,000
Cash and cash equivalents at beginning of period	32,093,000	38,501,000	38,501,000
Cash and cash equivalents at end of period	28,989,000	48,773,000	$ 32,093,000
Supplemental disclosures of non-cash investing and financing cash flow information:
Conversion of Series B preferred		$ 7,000